Adamas Pharmaceuticals
Create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology.
Launch date
Employees
Market cap
-
Enterprise valuation
€364m (Public information from Oct 2021)
Share price
$8.22 ADMS
Emeryville California (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 34.0m | 54.0m | 74.0m | 93.0m | 125m |
| % growth | - | - | - | 59 % | 37 % | 26 % | 34 % |
| EBITDA | - | (86.0m) | (114m) | (91.0m) | (38.0m) | (26.0m) | - |
| % EBITDA margin | - | - | (335 %) | (169 %) | (51 %) | (28 %) | - |
| Profit | - | (89.0m) | (131m) | (105m) | (57.0m) | (43.0m) | (15.0m) |
| % profit margin | - | - | (385 %) | (194 %) | (77 %) | (46 %) | (12 %) |
| EV / revenue | - | - | 4.2x | 2.1x | 2.4x | - | - |
| EV / EBITDA | - | -9.0x | -1.3x | -1.2x | -4.7x | - | - |
| R&D budget | 31.9m | - | 37.4m | - | - | - | - |
| R&D % of revenue | - | - | 110 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$21.0m | Series B | ||
| N/A | $13.0m | Series C | |
| N/A | $8.0m | Series C | |
$40.0m | Series D | ||
| N/A | N/A | IPO | |
* | N/A | $58.0m | Post IPO Equity |
* | N/A | $100m | Post IPO Equity |
* | N/A | $134m | Post IPO Equity |
* | N/A | $50.0m | Post IPO Equity |
| N/A | $59.2m | Post IPO Equity | |
$400m Valuation: $400m 5.4x EV/LTM Revenues -10.5x EV/LTM EBITDA | Acquisition | ||
| Total Funding | €74.5m | ||
Related Content
Recent News about Adamas Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.